Vaginal mucosa irritation testing is a critical biocompatibility study required for medical gels that contact vaginal tissue during gynecological examination, ultrasound imaging, treatment, or local drug delivery. Conducted in accordance with ISO 10993-23 and the GB/T 16886 series of standards, this test evaluates whether a gel formulation induces erythema, edema, or epithelial injury at the application site. This article explains the sample requirements, test items, experimental methodology, scoring criteria, and regulatory applications of vaginal mucosa irritation testing for medical gels.
Technical Overview
Medical gels intended for vaginal use, such as ultrasonic coupling gels, lubricants, moisturizers, and therapeutic or drug-device combination gels, contact mucosal tissue that is highly permeable and physiologically sensitive. Because the vaginal epithelium responds rapidly to changes in pH, osmolality, and chemical composition, regulatory authorities worldwide require objective evidence that such products do not cause local irritation before they may be placed on the market.
Vaginal mucosa irritation testing forms part of the biological evaluation program described in ISO 10993-1 (GB/T 16886.1). The specific test methods and interpretation criteria are defined in ISO 10993-23:2021, which superseded the irritation requirements formerly contained in ISO 10993-10. The corresponding Chinese national standard is GB/T 16886.23. The study assesses both macroscopic tissue reactions, such as erythema and edema, and microscopic changes, including epithelial damage, leukocyte infiltration, vascular congestion, and tissue edema, following repeated exposure of the vaginal mucosa to the gel or to extracts prepared from it.
Test selection depends on the nature and duration of mucosal contact, classified in ISO 10993-1 as limited contact (24 hours or less), prolonged contact (24 hours to 30 days), or long-term contact (more than 30 days), and on whether the contacting surface is intact or breached mucosa. In line with the 3Rs principle of replacement, reduction, and refinement, validated in vitro methods based on reconstructed human vaginal epithelial tissues are increasingly accepted as an initial screening step before in vivo confirmation.
Testing Samples
Applicable Product Types
- Ultrasonic coupling gels used with transvaginal probes
- Lubricating gels for gynecological examinations, catheters, and medical instruments
- Vaginal moisturizing and hydrating gels containing hyaluronic acid or similar polymers
- Antimicrobial, anti-inflammatory, and mucosal repair gels for gynecological treatment
- Contraceptive and spermicidal gels
- Postoperative hemostatic, adhesion-prevention, and wound-repair gels
- Drug-device combination gels with topical or local action
Sample Preparation and Submission Requirements
Testing should be performed on the final product in its sterilized, clinically representative configuration, ideally from a batch manufactured under routine production conditions. Depending on the study design, the gel may be tested directly as received or as extracts prepared in accordance with ISO 10993-12, using polar media such as 0.9 percent sodium chloride solution or cell culture medium and, where chemically justified, non-polar media such as sesame seed oil. Standard extraction conditions include 37 degrees Celsius for 72 hours, 50 degrees Celsius for 72 hours, 70 degrees Celsius for 24 hours, or 121 degrees Celsius for 1 hour, selected according to the physicochemical stability of the formulation.
Typical submission requirements include the following:
- Sufficient quantity of the finished gel, commonly 50 to 100 mL per test plus retention samples
- Complete formulation information, including the polymer system, preservatives, and pH adjusters
- Physicochemical data such as pH value, osmolality, and viscosity
- Sterilization method and residual data, for example ethylene oxide residuals per ISO 10993-7 where applicable
- Declared intended use, contact duration, and contact category as stated in the registration file
Testing Items
A complete irritation assessment for a vaginal medical gel generally combines the core irritation study with supporting physicochemical and biological endpoints, tailored to the risk analysis documented under ISO 10993-1.
In Vivo Vaginal Mucosa Irritation Test
The reference method applies the gel or its extracts to the vaginal vault of healthy female rabbits or ovariectomized rats once daily for a defined period, followed by macroscopic scoring and histopathological examination of the vaginal tissue. This study directly demonstrates the local tolerance of the finished product under conditions that simulate clinical exposure.
In Vitro Irritation Screening
Reconstructed human vaginal epithelium tissue models allow topical application of the gel with quantitative endpoints such as tissue viability measured by MTT assay, the exposure time causing a 50 percent reduction in viability, and the release of inflammatory mediators such as interleukin-1 alpha and interleukin-8. In vitro data are particularly valuable during formulation screening and can support a waiver or reduction of animal testing when scientifically justified under ISO 10993-23.
Supporting Physicochemical Evaluations
- pH measurement: vaginal physiology is mildly acidic at approximately pH 3.8 to 4.5, and strongly deviant gel pH is a recognized irritation risk factor
- Osmolality: hyperosmolar formulations can induce epithelial dehydration and desquamation, and WHO guidance for intimate lubricants recommends keeping osmolality below approximately 1200 mOsm/kg
- Buffering capacity and viscosity, which influence retention time and exposure level at the mucosal surface
- Bioburden or sterility verification consistent with the claimed sterilization state of the product
Complementary Biocompatibility Endpoints
- Cytotoxicity testing in accordance with ISO 10993-5
- Sensitization testing in accordance with ISO 10993-10
- Chemical characterization of extractables and leachables per ISO 10993-18, supported by toxicological risk assessment per ISO 10993-17
Testing Methods
Animal Model and Grouping
The standard in vivo study uses healthy adult nulliparous female New Zealand White rabbits, typically three per group. Animals are acclimatized, randomized, and assigned to a test group, a vehicle or negative control group such as saline, and, where extracts are evaluated, a corresponding blank control group. Positive control substances such as nonoxynol-9 formulations may be included periodically to demonstrate test sensitivity under the laboratory quality system.
Exposure Procedure
A defined volume of gel, commonly 1 mL, is gently instilled into the vaginal vault using a soft catheter or applicator once daily for five consecutive days, unless the clinical use pattern justifies a different schedule, for example 10 or more days for prolonged-contact products. When extracts are evaluated, the same dosing regimen is applied to the polar and non-polar extracts and their corresponding blanks. Animals are observed daily for clinical signs, discharge, bleeding, or behavioral changes throughout the dosing period.
Macroscopic Scoring
Approximately 24 hours after the final exposure, the vaginal mucosa is examined visually and scored using a Draize-type scale from 0 to 4 for erythema and eschar formation and from 0 to 4 for edema at each tissue site.
Histopathological Evaluation
Vaginal tissues are excised, fixed in neutral buffered formalin, paraffin-embedded, sectioned, and stained with hematoxylin and eosin. A qualified veterinary pathologist scores four histological parameters, namely epithelial injury, leukocyte infiltration, vascular congestion, and edema, each on a 0 to 4 scale. Microscopic findings generally provide the most sensitive and regulatorily decisive evidence of mucosal tolerance.
Calculation and Interpretation of Results
The irritation index is calculated as the cumulative macroscopic and microscopic scores divided by the number of animals and the number of scoring occasions, normalized to the maximum attainable score. Responses are conventionally classified as negligible with an index of 0, slight from 0.1 to 2.0, moderate from 2.1 to 5.0, or severe above 5.0. A gel is considered acceptable when the irritation response of the test group does not exceed that of the control group in a statistically and biologically meaningful manner. Study validity requires that negative and vehicle control animals remain free of significant irritation and that dosing and observation records confirm full protocol compliance.
Applications
Regulatory Registration and Market Access
- Registration dossiers for gynecological medical gels submitted to the NMPA in China, where vaginal irritation data are a standard requirement for gynecological device files
- US FDA submissions, including 510(k) notifications and investigational device applications, supporting substantial equivalence or clinical study use of vaginal gels and lubricants
- EU MDR conformity assessments under Regulation (EU) 2017/745, in which notified bodies verify the biological evaluation file including mucosal irritation endpoints
- Acceptance in other jurisdictions such as Japan, Canada, and ASEAN markets under the IMDRF harmonized framework
Product Development and Change Management
- Comparative screening of candidate formulations, preservative systems, and pH adjusters during development
- Verification of biological safety after changes in raw material supplier, formulation, sterilization process, or primary packaging
- Support for biological evaluation reports required by periodic safety updates and post-market surveillance activities
Clinical and Scientific Documentation
Irritation study data are routinely included in investigator brochures, clinical trial applications, and scientific publications to substantiate the local safety profile of vaginal gel products before and during human exposure.
FAQ
Which standards govern vaginal mucosa irritation testing for medical gels?
The primary standard is ISO 10993-23:2021, which replaced the irritation requirements previously located in ISO 10993-10. In China, GB/T 16886.23 is the equivalent national standard. Test planning and sample preparation follow ISO 10993-1 and ISO 10993-12 respectively.
Can in vitro testing replace the animal study?
Validated reconstructed human vaginal epithelium models may serve as a standalone basis for an irritation conclusion when the device materials and contact conditions fall within the applicability domain of the method and the risk assessment supports it. In practice, many regulatory submissions still include the in vivo rabbit study or a justified combination of in vitro data, chemical characterization, and literature evidence.
How much sample is required and how long does testing take?
Most studies require approximately 50 to 100 mL of the finished gel, or an equivalent quantity for extraction, together with documented formulation and physicochemical information. The in vivo study, including acclimatization, dosing, histopathology, and reporting, typically takes four to six weeks, while in vitro screening can often be completed within one to two weeks.
What result is considered a pass?
A gel passes when it produces no irritation response, or a response not greater than that of the control group, with histological parameters within the negligible or slight range and no biologically significant epithelial injury. The final conclusion is drawn by comparing the calculated irritation index against the control group and the standard classification categories.
Is testing mandatory for short-contact products such as transvaginal ultrasound gels?
Even gels with limited contact duration fall within the scope of ISO 10993-1 biological evaluation. A documented risk assessment may justify waiving specific tests when chemically identical materials with established safety histories are used, but novel formulations or new material suppliers generally require at least screening-level irritation evaluation.
Where should the testing be performed?
Studies should be conducted by accredited third-party laboratories or qualified research institutions operating under GLP or ISO/IEC 17025 quality systems, with validated methods, appropriately licensed animal facilities where applicable, and demonstrated experience in medical device biocompatibility evaluation.